B. Riley, Foghorn Therapeutics
B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...
B. Riley Financial Inc (NASDAQ:RILY). has paused the payment of dividends on two of its preferred stock offerings. The ...
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...
Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.
Analysts at B. Riley reduced their FY2024 earnings estimates for shares of Ladder Capital in a research report issued to clients and investors on Monday, January 27th. B. Riley analyst R. Binner now ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Chairman Bryant Riley has put a priority on paying down debt as his firm seeks to recover from a string of losses.
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.97% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback